UNIVERSITI PUTRA MALAYSIA

POSSIBLE ANTINOCICEPTIVE MECHANISM AND SITE OF ACTIVITY OF HARUAN (Channa striatus) CRUDE AQUEOUS EXTRACT IN MICE

ZAINUL AMIRUDDIN B. ZAKAFUA

FPSK(P) 2005 5
POSSIBLE ANTINOCICEPTIVE MECHANISM AND SITE OF ACTIVITY OF HARUAN (Channa striatus) CRUDE AQUEOUS EXTRACT IN MICE

By

ZAINUL AMIRUDDIN B. ZAKARIA

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Doctor of Philosophy

October 2005
DEDICATION

This thesis is dedicated to all of the following people who have inspired me in a very special way that only I can understand:

MYSELF ~ For what I am!!!
MAK and ABAH ~ For bringing me here!!!
SHARIAH LOH LONG ~ For her eternal love and patience!!!
MUHAMMAD AFIQ AHLAMI ~ For reminding me not to give up!!!
MY FAMILY ~ For being there!!!
MY SUPERVISOR and CO-SUPERVISORS ~ For trusting me!!!

“It is better to burn out than to fade away…

Peace. Love. Empathy.”
The present study was carried out to determine the possible mechanism of antinociception and site of activity of the crude aqueous extract of Haruan (Channa striatus) (ASH) in mice using the abdominal constriction test. The ASH, obtained after chloroform:methanol (CM) (2:1; v/v) extraction (24 hrs) of the fresh Haruan fillet, was evaporated to remove the methanol residue and used throughout the study. The first study was carried out to ascertain the dry weight and antinociceptive profile of ASH. The second study was carried out to determine the amino acids and fatty acids compositions, as well as the polypeptide profile of ASH. The third study was carried out to determine the actual onset and offset of ASH activity after its subcutaneous (SC) or intraperitoneal (IP) administration at four different sets of time (0, 5, 30 and 60 min). The fourth and fifth studies were carried out to determine the involvement of opioid and non-opioid receptors, respectively, in the ASH antinociceptive activity. All of the antagonists of opioidergic, muscarinic, nicotinic, α- and β-adrenergic, dopaminergic, serotonergic and γ-aminobutyric acid (GABA) receptors were administered (SC) 10 min prior to ASH (SC) administration. The sixth study was carried out to determine the role of L-
arginine/nitric oxide/cyclic 3'5'-guanosine monophosphate (L-arginine/NO/cGMP) pathway in the ASH antinociceptive activity. The precursor (L-arginine) and inhibitor (N\textsuperscript{G}-nitro-L-arginine methyl esters (L-NAME)) for NO, as well as the inhibitor for cGMP (methylene blue (MB), were administered (SC) 5 min before ASH administration (SC). In all of the above-mentioned studies that involved the use of antinociceptive test, the 0.6% acetic acid-induced abdominal constriction test in mice was used as an assay to evaluate the ASH antinociceptive activity. All data obtained were analysed using the One-way Analysis of Variance (ANOVA) followed by the Tukey test with $P<0.05$ as the limit of significance.

From the data obtained, the ASH, which exhibited significant ($P<0.05$) and concentration/dosage-dependent antinociceptive activity, yielded 1.89g/10.0ml of white coloured powder after subjection to the freeze-drying process. The ASH was also found to contain all the important amino acids with major amino acids found are glycine (35.77% ± 0.58), alanine (10.19% ± 1.27), lysine (9.44 ± 0.56), aspartic acid (8.53 ± 1.15) and proline (6.86% ± 0.78). Furthermore, the ASH was also found to contain high composition of palmitic acid (C16:0) (35.93% ± 0.63), oleic acid (C18:1) (22.96% ± 0.40), stearic acid (C18:0) (15.31% ± 0.33), linoleic acid (C18:2) (11.45% ± 0.31) and arachidonic acid (C20:4) (7.44% ± 0.83). The ASH was also found to produce at least four major fractions (at the retention times of 8.919, 9.841, 10.263 and 10.744), when subjected to the high performance liquid chromatography (HPLC) process, that are believed to be polypeptides. The onset time and the offset time of the ASH antinociceptive activity, which are concentration-dependent and concentration-
independent, occurred between 0 to 5 min, and 60 min after its SC administration. Interestingly, changing the route of administration from SC to IP caused significant (P<0.05) increase in the ASH antinociceptive activity with the concentration-independent onset time of activity observed immediately after the ASH administration with no apparent offset time. The activity was found to reach the maximum effect 30 min after the ASH administration regardless of the route of administration used. Pretreatment with naloxone at all dosages did not cause any significant changes in the ASH antinociceptive activity indicating that the activity did not involve an opioid receptor mechanism, and thus confirmed the report made by Dambisya et al. (1999). Pre-treatment with various types of non-opioid receptor antagonists demonstrated the involvement of at least four types of receptors (muscarinic, GABA_A, α-adrenergic and serotonergic) in the mechanism of ASH antinociceptive activity. Pre-treatment with atropine and bicuculine almost completely blocked (P<0.05), while pre-treatment with phenoxybenzamine and methysergide significantly (P<0.05) reduced half of the ASH activity. The role of L-arginine/NO/cGMP pathway in ASH antinociceptive activity was also observed after pretreatment of the ASH with L-arginine, L-NAME or MB, but not with D-arginine. Pretreatment with L-arginine was found to significantly (P<0.05) reduce the ASH antinociceptive activity, whereas pretreatment with L-NAME or MB were found to enhance (P<0.05) the activity. Based on the finding, low concentration of NO, limited by the presence of higher concentration of ASH, and inhibition of cGMP system play important role in ASH antinociceptive activity. However, the actual mechanism underlying this phenomenon is yet to be fully understood.
As a conclusion, we suggest that the ASH-produced antinociceptive activity could be due to the presence of various types of amino acids and fatty acids, as well as four major fractions, and involved activation of at least four types of the non-opioid receptors (namely the muscarinic, GABA<sub>A</sub>, α-adrenergic and serotonergic) and the L-arginine/NO/cGMP pathway.
Mekanisma dan Tapak Tindakan Antinosiseptif yang Mungkin Bagi Ekstrak Akues Kasar Haruan (Channa striatus) dalam Mencit

Oleh

Zainul Amiruddin B. Zakaria

Oktober 2005

Pengerusi: Prof. Madya Moh. Roslan Sulaiman, PhD

Fakulti: Perubatan dan Sains Kesihatan

Kajian terkini ini dijalankan untuk menentukan mekanisme dan tapak tindakan antinosiseptif yang mungkin terlibat bagi ekstrak akues kasar Haruan (Channa striatus) (ASH) dengan menggunakan ujian pencerutan abdominal keatas mencit. ASH, diperolehi selepas pengekstrakan (24 jam) filet segar Haruan menggunakan kloroform:metanol (CM) (2:1; v/v), dievaporasikan untuk menyingkirkan residu metanol dan digunakan sepanjang kajian dijalankan. Kajian pertama dijalankan bagi menentukan berat kering dan profil antinosiseptif bagi ASH. Kajian kedua dijalankan untuk menentukan komposisi asid-asid amino dan asid-asid lemak, serta profil polipeptida bagi ASH. Kajian ketiga dijalankan untuk menentukan masa sebenar bermula dan berakhirnya aktiviti antinosiseptif ASH selepas pemberian secara subkutaneus (SC) atau intraperitonial (IP) pada empat set masa yang berbeza (0, 5, 30 dan 60 min). Kajian keempat dan kelima dijalankan untuk menentukan penglibatan reseptor-reseptor opioid dan bukan-opioid, masing-masing, dalam aktiviti antinosiseptif ASH. Kesemua antagonist-antagonis bagi reseptor-reseptor opioidergik, muskarinik, nikotinik, α- dan β-adrenergik, dopaminergik, serotonergik dan asid γ-aminobutirik (GABA), diberikan (SC) 10 min sebelum
pemberian ASH (SC). Kajian keenam dijalankan untuk menentukan peranan laluan L-arginina/nitrik oksida/3':5'-guanosina monofosfat siklik (L-arginine/NO/cGMP) dalam aktiviti antinosiseptif ASH. Prekursor (L-arginina) dan perencat (N^G-nitro-L-arginina metil ester (L-NAME)) bagi NO, serta perencat (metilena biru (MB)) bagi cGMP, diberikan (SC) 5 min sebelum pemberian ASH (SC). Dalam kesemua kajian yang dinyatakan di atas yang melibatkan penggunaan ujian antinosiseptif, ujian pencerutan abdominal keatas mencit yang dicetus oleh 0.6% asid asetik telah digunakan sebagai assai untuk menilai aktiviti antinosiseptif ASH. Kesemua data yang telah diperolehi dianalisa menggunakan One-way Analysis of Variance (ANOVA) diikuti oleh ujian Tukey dengan P<0.05 sebagai had bererti.

Dari data yang telah diperolehi, ASH, yang menunjukkan aktiviti antinosiseptif yang bererti (P<0.05) dan bergantung kepada kepekatan/dos, telah menghasilkan 1.89g/10.0ml serbuk berwarna putih selepas menjalani proses beku-kering. ASH juga didapati mengandungi kesemua asid-asid amino penting dengan asid-asid amino utama yang didapati adalah glisina (35.77% ± 0.58), alanina (10.19% ± 1.27), lisina (9.44 ± 0.56), asid aspartik (8.53 ± 1.15) dan prolina (6.86% ± 0.78). Tambahan pula, ASH juga didapati mengandungi komposisi tinggi asid palmitik (C16:0) (35.93% ± 0.63), asid oleik (C18:1) (22.96% ± 0.40), asid stearik (C18:0) (15.31% ± 0.33), asid linoleik (C18:2) (11.45% ± 0.31) dan asid arakidonik (C20:4) (7.44 ± 0.83). ASH juga didapati menghasilkan empat fraksi utama (pada masa penahanan iaitu 8.919, 9.841, 10.263 dan 10.744) apabila didedahkan kepada kromatografi cecair berprestasi tinggi (HPLC), yang dipercayai adalah polipeptida-polipeptida. Masa bermula dan berakhirnya aktiviti
antinosiseptif ASH, yang bergantung dan tidak bergantung kepada kepekatan, masing-
masing terhasil diantara 0 dan 5 min, dan 60 min selepas pemberianinya secara SC. Yang
menariknya, penukaran kaedah pemberian dari SC kepada IP menyebabkan peningkatan
yang bererti (P<0.05) dalam aktiviti antinosiseptif ASH dengan masa bermulanya aktiviti,
yang tidak bergantung kepada kepekatan, dilihat serta-merta selepas pemberian ASH
tanpa masa berakhir yang nyata. Aktiviti tersebut juga didapati mencapai kesan
maksimum 30 min selepas pemberian ASH tanpa mengambilkira kaedah pemberian yang
digunakan. Pra-rawatan dengan nalokson pada semua dos tidak menyebabkan sebarang
perubahan bererti dalam aktiviti antinosiseptif ASH menunjukkan bahawa aktiviti
tersebut tidak melibatkan mekanisme reseptor opioid dan, dengan itu mengesahkan
laporan yang dibuat oleh Dambisya et al. (1999). Pra-rawatan dengan pelbagai jenis
antagonis-antagonis reseptor menunjukkan penglibatan sekurang-kurangnya empat jenis
reseptor (muskarinik, GABA_A, α-adrenergik and serotonergik) dalam mekanisme aktiviti
antinosiseptif ASH. Pra-rawatan dengan atropina dan bikukulina menghalang hampir
keseluruhan (P<0.05), manakala pra-rawatan dengan fenoksibenzamina dan
methysergide menurunkan secara bererti (P<0.05) separuh dari aktiviti ASH. Peranan
laluan L-arginine/NO/cGMP dalam aktiviti antinosiseptif ASH juga dapat dilihat selepas
pra-rawatan keatas ASH dengan L-arginina, L-NAME atau MB, tetapi tidak D-argininna.
Pra-rawatan dengan L-arginine telah didapati menurunkan aktiviti antinosispetif ASH
secara bererti (P<0.05), manakala pra-rawatan dengan L-NAME atau MB telah didapati
meningkatkan (P<0.05) aktiviti itu. Berdasarkan penemuan ini, kepekatan rendah NO,
yang mana dipengaruhi oleh kehadiran ASH dalam kepekatan tinggi, dan perencatan
sistem cGMP memainkan peranan penting dalam aktiviti antinosiseptif ASH.
Walaubagaimanapun, mekanisme sebenar yang mendasari fenomena ini masih belum dapat difahami sepenuhnya.

Sebagai kesimpulannya, kami mencadangkan bahawa aktiviti antinosiseptif yang dihasilkan oleh ASH adalah disebabkan oleh kehadiran pelbagai jenis asid-asid amino dan asid-asid lemak, serta kehadiran sekurang-kurangnya empat jenis fraksi-fraksi utama, dan melibatkan pengaktifan, sekurang-kurangnya, empat jenis reseptor-reseptor bukan opioid (iaitu muskarinik, GABA, α-adrenergik dan serotonergik) dan laluan L-arginine/NO/cGMP.
ACKNOWLEDGEMENTS

“In the name of ALLAH S.W.T., the Most Benevolent and Most Merciful.

All gratifications are referred to ALLAH S.W.T.”

I would like to take this opportunity to thank the chairman of my supervisory committee, Associate Professor Dr. Mohd. Roslan B. Sulaiman, who has been like a brother to me, whose expert guidance and support has helped me to complete this research. His kindness, affection, encouragement and moral support gave me the courage and ability to overcome all the problems I have faced from time to time during the course of my work. I would like to extend my heartfelt appreciation to him for his invaluable advice and continuous comments, which brighten my future through the experiences that I have gained from him.

I am also very grateful to Associate Professor Dr. Muhammad Nazrul Hakim B. Abdullah, who has also been like a brother to me, whose expert guidance and support has helped me to overcome most of the problems that I have encountered during the course of my study. I would also like to express my appreciation for his willingness to lend me financial support so that I can purchase some of the chemicals needed for my study.

I am also indebted to and wish to express my special appreciation to my mentor and former chairman of the supervisory committee, Associate Professor Dr. Abdul Manan B. Mat Jais, whom I have known for the past eight years and who have been like a father to
me, for his interest and invaluable suggestions that had enabled me to carry on with my project successfully.

I am also very grateful to Professor Emeritus Terrence George Baker from Bradford University, who spent some of his time during his visit to College University of Technology and Management Malaysia, Shah Alam to read the draft of my thesis, and also for his invaluable comments, suggestions and advice.

I would also like to express my appreciation to all the staff of the Physiology Laboratory, Department of Biomedical Sciences especially Mr. Johari B. Ripin who has helped me in my research projects and who has been my best friend for the past eight years. I would also like to extend my appreciation to Mr. Kufli B. Che Nor who has supplied mice continuously whenever I needed them and, Mrs. Zainab Bt. Nasri and Mrs. Rosmawati Bt. Hanipah for their kindness, assistance and cooperation during the preparation of chemical solutions.

I would like to thank the Ministry of Science, Technology and Environmental for their belief in me and for providing me a scholarship (National Science Fellowship), which has enabled me to continue my research project as well as my life as a student.

The list of thanks also goes to all of my friends and the people who have known me for the joy and laughter and memories that we have shared together during my study at Universiti Putra Malaysia. Lastly, I would like to express my most sincere and warmest
gratitude to my mother, my father, my wife (Shariah Loh Bt. Long) and my son (Muhammad Afiq Ahlami) and all of my family members for their prayers, love, generosity and moral inputs that they have provided me during the course of my study.
I certify that an Examination Committee met on October 3rd 2005 to conduct the final examination of Zainul Amiruddin B. Zakaria on his Doctor of Philosophy thesis entitled “Possible Antinociceptive Mechanism and Site of Activity of Haruan (Channa striatus) Crude Aqueous Extract in Mice” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

NASARUDDIN ABDUL AZIZ, M. Med. Sc.
Associate Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Chairman)

DATO’ ABDUL SALAM ABDULLAH, PhD
Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
/Internal Examiner)

MOHAMED ALI RAJION, PhD
Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Internal Examiner)

ZHARI ISMAIL, PhD
Professor
Center of Study of Pharmacy Science
Universiti Sains Malaysia
(External Examiner)

ZAKARIAH ABDUL RASHID, PhD
Professor/Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 27 DEC 2005
This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee are as follows:

MOHD. ROSLAN SULAIMAN, PhD
Associate Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Chairman)

ABDUL MANAN MAT JAIS, PhD
Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Member)

MUHAMMAD NAZRUL HAKIM ABDULLAH, PhD
Associate Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Member)

Signature

AINI IDERIS, PhD
Professor/Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 12 JAN 2006
DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.

ZAINUL AMIRUDDIN B. ZAKARIA

Date: 23/12/2005

XVI
TABLE OF CONTENTS

DEDICATION II
ABSTRACT III
ABSTRAK VII
ACKNOWLEDGEMENTS XI
APPROVAL XIV
DECLARATION XVI
LIST OF TABLES XXII
LIST OF FIGURES XXIV
LIST OF ABBREVIATIONS XXVI

CHAPTER

1 INTRODUCTION 1
1.1 Natural Products 2
1.2 Marine Natural Products 3
1.3 Haruan (Channa striatus) 4
1.4 The Objectives of the Study 6

2 LITERATURE REVIEW 7
2.1 Natural Products 7
2.2 Marine Natural Products: Significance and Overview 7
2.3 Analgesic Compounds 11
  2.3.1 Opioid Analgesic Compounds 12
  2.3.2 Non-opioid Analgesic Compounds 13
  2.3.3 Natural Analgesic Compounds 13
  2.3.4 Plant-derived Natural Analgesic Compounds 14
  2.3.5 Animal-derived Natural Analgesic Compounds 15
  2.3.6 Other Analgesic Compounds 22
2.4 Aspirin – A NSAID’s with Analgesic Properties 23
2.5 Haruan 24
2.6 Pain 27
  2.6.1 Mechanism of Pain 28
2.7 Nociceptors 30
  2.7.1 Nociception Neurons 37
2.8 Drug Receptors 38
  2.8.1 Types of Drug Receptors 40
    2.8.1.1 Opioid Receptors 40
    2.8.1.2 Serotonergic Receptors 41
    2.8.1.3 Cholinergic Receptors 43
    2.8.1.4 Adrenergic Receptors 46

XVII
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9 Reports on Involvement of Receptors in Pain Modulation</td>
<td>49</td>
</tr>
<tr>
<td>2.9.1 Peripheral Receptor Systems Mediating Antinociceptive Activity</td>
<td></td>
</tr>
<tr>
<td>2.10 Nitric Oxide</td>
<td>56</td>
</tr>
<tr>
<td>2.10.1 NO System Involvement in Pain Modulation</td>
<td>58</td>
</tr>
<tr>
<td>2.11 Countering Pain</td>
<td>59</td>
</tr>
<tr>
<td>2.11.1 The Role of Capsaicin Receptors</td>
<td>59</td>
</tr>
<tr>
<td>2.11.2 The Role of Sodium (Na⁺) Channels</td>
<td>61</td>
</tr>
<tr>
<td>2.11.3 The Role of Protein Kinase C (PKC)</td>
<td>62</td>
</tr>
<tr>
<td>2.11.4 The Next Steps</td>
<td>63</td>
</tr>
<tr>
<td>2.12 Antinociceptive Assay</td>
<td>63</td>
</tr>
<tr>
<td>2.13 Justification and Basis for Conducting the Present Study</td>
<td>64</td>
</tr>
<tr>
<td>3 GENERAL MATERIALS AND METHODS</td>
<td>68</td>
</tr>
<tr>
<td>3.1 Materials and Methods</td>
<td>68</td>
</tr>
<tr>
<td>3.1.1 Preparation of Fresh Haruan Fillet</td>
<td>68</td>
</tr>
<tr>
<td>3.1.2 Preparation of Crude Aqueous Supernatant of Haruan (ASH)</td>
<td>68</td>
</tr>
<tr>
<td>3.1.3 Determination of Actual Amount of Crude Dried Compound Present in ASH</td>
<td>69</td>
</tr>
<tr>
<td>3.1.4 Antinociceptive Study</td>
<td>69</td>
</tr>
<tr>
<td>3.1.4.1 Preparation of Different Concentrations of ASH</td>
<td>69</td>
</tr>
<tr>
<td>3.1.4.2 Preparation of the Dosage of Drug</td>
<td>70</td>
</tr>
<tr>
<td>3.1.4.3 Experimental Animals</td>
<td>70</td>
</tr>
<tr>
<td>3.1.4.4 Establishment of the Antinociceptive Profile of ASH</td>
<td>71</td>
</tr>
<tr>
<td>3.1.4.5 Antinociceptive Assay</td>
<td>71</td>
</tr>
<tr>
<td>3.1.5 Statistical Analysis</td>
<td>72</td>
</tr>
<tr>
<td>3.2 Results</td>
<td>73</td>
</tr>
<tr>
<td>3.2.1 The Actual Amount and Percentage Yield of Crude Dried Compound Present in ASH</td>
<td>73</td>
</tr>
<tr>
<td>3.2.2 The Antinociceptive Activity of ASH</td>
<td>73</td>
</tr>
<tr>
<td>3.3 Discussion</td>
<td>77</td>
</tr>
<tr>
<td>4 DETERMINATION OF AMINO ACID AND FATTY ACID COMPOSITION, AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY PROFILES OF CRUDE AQUEOUS EXTRACT OF HARUAN (Channa striatus)</td>
<td>80</td>
</tr>
<tr>
<td>4.1 Introduction</td>
<td>80</td>
</tr>
<tr>
<td>4.2 Materials and Methods</td>
<td>82</td>
</tr>
<tr>
<td>4.2.1 Determination of Amino Acid and Fatty Acid Composition of ASH</td>
<td>82</td>
</tr>
</tbody>
</table>
4.2.1.1 Determination of Amino Acid Composition of ASH

4.2.1.2 Determination of Fatty Acid Composition of ASH

4.2.1.3 High Performance Liquid Chromatography Profiling of ASH

4.2.2 Statistical Analysis

4.3 Results

4.3.1 The Amino Acid and Fatty Acid Composition of ASH

4.3.2 The HPLC Profile of ASH

4.4 Discussion

5 DETERMINATION OF THE ONSET AND OFFSET TIME OF CRUDE AQUEOUS EXTRACT OF HARUAN (Channa striatus) ANTINOCICEPTIVE ACTIVITY ADMINISTERED SUBCUTANEously AND INTRAPERITONEALLY IN MICE

5.1 Introduction

5.2 Materials and Methods

5.2.1 Preparation of Dosages of ASH

5.2.2 Preparation of the Dosage of Drug

5.2.3 Experimental Animals

5.2.4 Antinociceptive Assay

5.2.5 Statistical Analysis

5.3 Results

5.3.1 The Antinociceptive Activity of ASH Administered Subcutaneously

5.3.2 Comparison of the SC-administered ASH Antinociceptive Activity at the Respective Time Against the Control Group

5.3.3 The Antinociceptive Activity of ASH Administered Intraperitoneally

5.3.4 Comparison of the IP-administered ASH Activity at the Respective Time Against the Control Group

5.3.5 Comparison of the Effect of Changing the Route of Administration on the Antinociceptive Activity of ASH

5.4 Discussion

6 ELUCIDATION OF THE INVOLVEMENT OF OPIOID RECEPTOR IN CRUDE AQUEOUS EXTRACT OF

XIX
### 6.1 Introduction

### 6.2 Materials and Methods
- 6.2.1 Preparation of Dosages of ASH
- 6.2.2 Preparation of the Dosage of Drug
- 6.2.3 Experimental Animals
- 6.2.4 Antinociceptive Assay
- 6.2.5 Statistical Analysis

### 6.3 Results

### 6.4 Discussion

## 7

### 7.1 Introduction

### 7.2 Materials and Methods
- 7.2.1 Preparation of the Dosage of ASH
- 7.2.2 Preparation of the Dosage of Drugs
- 7.2.3 Experimental Animals
- 7.2.4 Antinociceptive Assay
- 7.2.5 Statistical Analysis

### 7.3 Results

### 7.4 Discussion

## 8

### 8.1 Introduction

### 8.2 Materials and Methods
- 8.2.1 Preparation of Dosage of ASH
- 8.2.2 Preparation of the Dosage of Drugs
- 8.2.3 Experimental Animals
- 8.2.4 Antinociceptive Assay
- 8.2.5 Statistical Analysis

### 8.3 Results
- 8.3.1 Effect of Pretreatment of DH2O, Aspirin and ASH with L-arginine, D-arginine, L-NAME and MB
- 8.3.2 Effect of Pretreatment of DH2O, Aspirin and ASH with Combination of L-arginine and L-NAME or MB

---

HARUAN *(Channa striatus)* ANTINOCICEPTIVE ACTIVITY IN MICE

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>128</td>
</tr>
</tbody>
</table>

| 6.1 Introduction | 128 |
| 6.2 Materials and Methods |
| 6.2.1 Preparation of Dosages of ASH | 130 |
| 6.2.2 Preparation of the Dosage of Drug | 130 |
| 6.2.3 Experimental Animals | 130 |
| 6.2.4 Antinociceptive Assay | 131 |
| 6.2.5 Statistical Analysis | 131 |

| 6.3 Results | 132 |
| 6.4 Discussion | 135 |

---

EFFECTS OF VARIOUS RECEPTOR ANTAGONISTS ON THE CRUDE AQUEOUS EXTRACT OF HARUAN *(Channa striatus)* ANTINOCICEPTIVE ACTIVITY IN MICE

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>138</td>
</tr>
</tbody>
</table>

| 7.1 Introduction | 138 |
| 7.2 Materials and Methods |
| 7.2.1 Preparation of the Dosage of ASH | 139 |
| 7.2.2 Preparation of the Dosage of Drugs | 139 |
| 7.2.3 Experimental Animals | 139 |
| 7.2.4 Antinociceptive Assay | 140 |
| 7.2.5 Statistical Analysis | 140 |

| 7.3 Results | 141 |
| 7.4 Discussion | 143 |

---

THE INVOLVEMENT OF PERIPHERAL L-ARGININE/NO/CGMP PATHWAY IN THE CRUDE AQUEOUS EXTRACT OF HARUAN *(Channa striatus)* ANTINOCICEPTIVE ACTIVITY IN MICE

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>152</td>
</tr>
</tbody>
</table>

| 8.1 Introduction | 152 |
| 8.2 Materials and Methods |
| 8.2.1 Preparation of Dosage of ASH | 154 |
| 8.2.2 Preparation of the Dosage of Drugs | 154 |
| 8.2.3 Experimental Animals | 154 |
| 8.2.4 Antinociceptive Assay | 155 |
| 8.2.5 Statistical Analysis | 155 |

| 8.3 Results |
| 8.3.1 Effect of Pretreatment of DH2O, Aspirin and ASH with L-arginine, D-arginine, L-NAME and MB | 156 |
| 8.3.2 Effect of Pretreatment of DH2O, Aspirin and ASH with Combination of L-arginine and L-NAME or MB | 162 |
8.4 Discussion

9 GENERAL DISCUSSION AND CONCLUSION

10 SUMMARY AND CONCLUSION

REFERENCES

APPENDICES

BIODATA OF THE AUTHOR
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The Amino Acid Composition of ASH</td>
<td>89</td>
</tr>
<tr>
<td>2</td>
<td>The Fatty Acid Composition of ASH</td>
<td>91</td>
</tr>
<tr>
<td>3</td>
<td>The Amino Acid Composition of <em>C. striatus</em> (adapted from Mat Jais <em>et al.</em>, 1994)</td>
<td>94</td>
</tr>
<tr>
<td>4</td>
<td>The Fatty Acid Composition of <em>C. striatus</em> (adapted from Mat Jais <em>et al.</em>, 1994)</td>
<td>95</td>
</tr>
<tr>
<td>5</td>
<td>The Antinociceptive Activity Profile of DH2O Administered SC at Different Set of Time (min) (Negative Control Group)</td>
<td>104</td>
</tr>
<tr>
<td>6</td>
<td>The Antinociceptive Activity Profile of Aspirin Administered SC at Different Set of Time (min) (Positive Control Group)</td>
<td>105</td>
</tr>
<tr>
<td>7</td>
<td>The Antinociceptive Activity Profile of 18.93 mg/kg ASH Administered SC at Different Set of Time (min)</td>
<td>105</td>
</tr>
<tr>
<td>8</td>
<td>The Antinociceptive Activity Profile of 47.33 mg/kg ASH Administered SC at Different Set of Time (min)</td>
<td>106</td>
</tr>
<tr>
<td>9</td>
<td>The Antinociceptive Activity Profile of 189.33 mg/kg ASH Administered SC at Different Set of Time (min)</td>
<td>106</td>
</tr>
<tr>
<td>10</td>
<td>The Antinociceptive Activity Profile of DH2O Administered IP at Different Set of Time (min) (Negative Control Group)</td>
<td>109</td>
</tr>
<tr>
<td>11</td>
<td>The Antinociceptive Activity Profile of Aspirin Administered IP at Different Set of Time (min) (Positive Control Group)</td>
<td>110</td>
</tr>
<tr>
<td>12</td>
<td>The Antinociceptive Activity Profile of 18.93 mg/kg ASH Administered IP at Different Set of Time (min)</td>
<td>110</td>
</tr>
<tr>
<td>Table</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>13</td>
<td>The Antinociceptive Activity Profile of 47.33 mg/kg ASH Administered IP at Different Set of Time (min)</td>
<td>111</td>
</tr>
<tr>
<td>14</td>
<td>The Antinociceptive Activity Profile of 189.33 mg/kg ASH Administered IP at Different Set of Time (min)</td>
<td>112</td>
</tr>
</tbody>
</table>
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Haruan (<em>Channa striatus</em>), a Freshwater Fish</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>Nociceptor and Pain Pathway (modified from Kibiuk, 1995)</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td>Activation of Specific Receptors for Tissue-damaging Stimuli (modified from Kandel et al. (2000))</td>
<td>33</td>
</tr>
<tr>
<td>4</td>
<td>Pathways and Chemicals Involved in Pain (modified from Rang et al. (1994))</td>
<td>34</td>
</tr>
<tr>
<td>5</td>
<td>Production of Prostaglandins and Other Inflammatory Mediators (modified from Kalant et al. (1985))</td>
<td>36</td>
</tr>
<tr>
<td>6</td>
<td>The Dried Sample of ASH Obtained After Freeze-drying for 48h</td>
<td>74</td>
</tr>
<tr>
<td>7</td>
<td>The Antinociceptive Profile of ASH Against the Control Groups</td>
<td>76</td>
</tr>
<tr>
<td>8</td>
<td>The Amino Acid Profiling of ASH</td>
<td>88</td>
</tr>
<tr>
<td>9</td>
<td>The Fatty Acid Profiling of ASH</td>
<td>90</td>
</tr>
<tr>
<td>10</td>
<td>The HPLC Profiling of the ASH Demonstrated the Presence of Four Major Fractions Labeled as A, B, C and D</td>
<td>92</td>
</tr>
<tr>
<td>11</td>
<td>Comparison of the Effect of SC-administered ASH Against the Control Groups at Their Respective Time of Administration</td>
<td>107</td>
</tr>
<tr>
<td>12</td>
<td>Comparison of the Effect of IP-administered ASH Against the Control Groups at Their Respective Time of Administration</td>
<td>113</td>
</tr>
<tr>
<td>13</td>
<td>Comparisons of the Effect of SC- or IP-injected ASH after 0 Min of Administration</td>
<td>115</td>
</tr>
</tbody>
</table>